{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:26:13Z","timestamp":1788279973308,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T00:00:00Z","timestamp":1468800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T00:00:00Z","timestamp":1468800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s12325-016-0374-x","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T13:31:37Z","timestamp":1468848697000},"page":"1519-1535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study"],"prefix":"10.1007","volume":"33","author":[{"given":"Yuuichi","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Shiino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setsuo","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,18]]},"reference":[{"key":"374_CR1","first-page":"11","volume":"241","author":"HM Mitchell","year":"1999","unstructured":"Mitchell HM. The epidemiology of Helicobacter pylori. Curr Top Microbiol Immunol. 1999;241:11\u201330.","journal-title":"Curr Top Microbiol Immunol"},{"key":"374_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ncpgasthep0634","volume":"3","author":"M Romano","year":"2006","unstructured":"Romano M, Ricci V, Zarrilli R. Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis\u2014implications for chemoprevention. Nat Clin Pract Gastroenterol Hepatol. 2006;3:622\u201332.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"9638","key":"374_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0140-6736(08)61159-9","volume":"372","author":"K Fukase","year":"2008","unstructured":"Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9638):392\u20137.","journal-title":"Lancet"},{"key":"374_CR4","doi-asserted-by":"publisher","first-page":"g3174","DOI":"10.1136\/bmj.g3174","volume":"348","author":"AC Ford","year":"2014","unstructured":"Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicopacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.","journal-title":"BMJ"},{"key":"374_CR5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1053\/gast.1996.v110.pm8613015","volume":"110","author":"RJ Hopkins","year":"1996","unstructured":"Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicopacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110:1244\u201352.","journal-title":"Gastroenterology"},{"key":"374_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3748\/wjg.v20.i3.665","volume":"20","author":"A Federico","year":"2014","unstructured":"Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol. 2014;20:665\u201372.","journal-title":"World J Gastroenterol"},{"key":"374_CR7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1056\/NEJMra020542","volume":"347","author":"S Suerbaum","year":"2002","unstructured":"Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175\u201386.","journal-title":"N Engl J Med"},{"key":"374_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-5378.2009.00738.x","volume":"15","author":"M Asaka","year":"2010","unstructured":"Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicopacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1\u201320.","journal-title":"Helicobacter"},{"key":"374_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicopacter pylori infection\u2014the Maastricht IV\/Florence consensus report. Gut. 2012;61:646\u201364.","journal-title":"Gut"},{"key":"374_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1586\/ecp.09.8","volume":"2","author":"A Mejia","year":"2009","unstructured":"Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295\u2013314.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"374_CR11","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3748\/wjg.v16.i19.2323","volume":"16","author":"AB Thomson","year":"2010","unstructured":"Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323\u201330.","journal-title":"World J Gastroenterol"},{"key":"374_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","volume":"19","author":"JM Shin","year":"2013","unstructured":"Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25\u201335.","journal-title":"J Neurogastroenterol Motil"},{"key":"374_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pharmthera.2005.05.005","volume":"108","author":"K Andersson","year":"2005","unstructured":"Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005;108:294\u2013307.","journal-title":"Pharmacol Ther"},{"key":"374_CR14","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1111\/j.1440-1746.2006.04717.x","volume":"21","author":"T Ang","year":"2006","unstructured":"Ang T, Fock K. Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol. 2006;21:S125\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"374_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1046\/j.1365-2036.2000.00775.x","volume":"14","author":"PO Katz","year":"2000","unstructured":"Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709\u201314.","journal-title":"Aliment Pharmacol Ther"},{"key":"374_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1067\/mcp.2001.113959","volume":"69","author":"T Furuta","year":"2001","unstructured":"Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicopacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69:158\u201368.","journal-title":"Clin Pharmacol Ther"},{"key":"374_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103\u201313.","journal-title":"Clin Pharmacol Ther"},{"key":"374_CR18","unstructured":"Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica (in press)."},{"key":"374_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"374_CR20","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin and Transl Gastroenterol. 2015;6:e94.","journal-title":"Clin and Transl Gastroenterol"},{"key":"374_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636\u201348.","journal-title":"Aliment Pharmacol Ther"},{"key":"374_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685\u201395.","journal-title":"Aliment Pharmacol Ther"},{"key":"374_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","volume":"37","author":"RS Wedemeyer","year":"2014","unstructured":"Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201\u201311.","journal-title":"Drug Saf"},{"key":"374_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.phrs.2003.10.010","volume":"49","author":"L Calabresi","year":"2004","unstructured":"Calabresi L, Pazzucconi F, Ferrara S, Di Paolo A, Tacca MD, Sirtori C. Pharmacokinetic interactions between omeprazole\/pantoprazole and clarithromycin in health volunteers. Pharmacol Res. 2004;49:493\u20139.","journal-title":"Pharmacol Res"},{"key":"374_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jac\/dkf172","volume":"50","author":"D Mainz","year":"2002","unstructured":"Mainz D, Borner K, Koeppe P, Kotwas J, Lode H. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. J Antimicrob Chemother. 2002;50:699\u2013706.","journal-title":"J Antimicrob Chemother"},{"key":"374_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1067\/mcp.2002.125559","volume":"72","author":"H Ushiama","year":"2002","unstructured":"Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicopacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002;72:33\u201343.","journal-title":"Clin Pharmacol Ther"},{"key":"374_CR27","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1128\/AAC.39.9.2078","volume":"39","author":"LE Gustavson","year":"1995","unstructured":"Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother. 1995;39:2078\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"374_CR28","unstructured":"Takecab (vonoprazan tablets): Japanese prescribing information. 2014. http:\/\/www.takedamed.com\/content\/medicine\/pdf\/pre-takecab.pdf. Accessed 24 Mar 2015."},{"key":"374_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311304","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicopacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016. doi:10.1136\/gutjnl-2015-311304.","journal-title":"Gut"},{"key":"374_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.39","author":"RH Hunt","year":"2015","unstructured":"Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Transl Gastroenterol. 2015. doi:10.1038\/ctg.2015.39.","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-016-0374-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0374-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:39:19Z","timestamp":1659098359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-016-0374-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,18]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0374-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,18]]},"assertion":[{"value":"8 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}